

## Texas Prior Authorization Program Clinical Criteria

---

### Drug/Drug Class

## Doxylamine/Pyridoxine

*This criteria was recommended for review by an MCO to ensure appropriate and safe utilization*

### Clinical Information Included in this Document

- **Drugs requiring prior authorization:** the list of drugs requiring prior authorization for this clinical criteria
- **Prior authorization criteria logic:** a description of how the prior authorization request will be evaluated against the clinical criteria rules
- **Logic diagram:** a visual depiction of the clinical criteria logic
- **Supporting tables:** a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable
- **References:** clinical publications and sources relevant to this clinical criteria

**Note:** Click the hyperlink to navigate directly to that section.

### Revision Notes

Updated with DUR Board recommendations



## Doxylamine/Pyridoxine

### Drugs Requiring Prior Authorization

The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit [TxVendorDrug.com/formulary/formulary-search](http://TxVendorDrug.com/formulary/formulary-search).

Drugs Requiring Prior Authorization	
Label Name	GCN
BONJESTA ER 20-20MG TABLET	42645
DICLEGIS DR 10-10MG TABLET	73860



## Doxylamine/Pyridoxine


### Clinical Criteria Logic

1. Does the client have a diagnosis of **nausea and vomiting associated with pregnancy** in the last 180 days?
  - Yes (Go to #2)
  - No (Deny)
  
2. Is the request for less than or equal to ( $\leq$ ) 2 tablets per day?
  - Yes (Approve – 180 days)
  - No (And the request is for Bonjesta, deny)
  - No (And the request is for Diclegis, go to #3)
  
3. Is the request for less than or equal to ( $\leq$ ) 4 tablets per day?
  - Yes (Approve – 180 days)
  - No (Deny)



# Doxylamine/Pyridoxine

## Clinical Criteria Logic Diagram





## Doxylamine/Pyridoxine

### Clinical Criteria Supporting Tables

<b>Step 2 (diagnosis of n/v associated with pregnancy)</b>	
<b>Required diagnosis: 1</b>	
<b>Look back timeframe: 180 days</b>	
<b>ICD-10 Code</b>	<b>Description</b>
O210	MILD HYPEREMESIS GRAVIDARUM
O211	HYPEREMESIS GRAVIDARUM WITH METABOLIC DISTURBANCE
O212	LATE VOMITING OF PREGNANCY
O218	OTHER VOMITING COMPLICATING PREGNANCY
O219	VOMITING OF PREGNANCY, UNSPECIFIED



## Doxylamine/Pyridoxine

### Clinical Criteria References

1. 2019 ICD-10-CM Diagnosis Codes. 2019. Available at [www.icd10data.com](http://www.icd10data.com). Accessed on October 25, 2019.
2. Clinical Pharmacology [online database]. Tampa, FL: Elsevier/Gold Standard, Inc.; 2019. Available at [www.clinicalpharmacology.com](http://www.clinicalpharmacology.com). Accessed on October 25, 2019.
3. Micromedex [online database]. Available at [www.micromedexsolutions.com](http://www.micromedexsolutions.com). Accessed on October 25, 2019.
4. Bonjesta Prescribing Information. Bryn Mawr, PA. Duchesnay USA, Inc. June 2018.
5. Diclegis Prescribing Information. Bryn Mawr, PA. Duchesnay USA, Inc. June 2018.
6. Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy. Obstet Gynecol 2018;131:e15.
7. Smith JA, Fox KA, Clark S. Treatment and Outcome of Nausea and Vomiting of Pregnancy. In CJ Lockwood (Ed.), UpToDate. August 2019.

## Publication History

The Publication History records the publication iterations and revisions to this document. Notes for the *most current revision* are also provided in the **Revision Notes** on the first page of this document.

Publication Date	Notes
10/25/2019	<ul style="list-style-type: none"><li>Initial publication and presentation to the DUR Board</li></ul>
10/29/2019	<ul style="list-style-type: none"><li>Updated with DUR Board recommendations</li></ul>